PHT Corporation Selects Hewlett Packard ElitePad 1000 with Windows 8.1 for SitePad® System in eClinical Research

PHT Corporation Selects Hewlett Packard ElitePad 1000 with Windows 8.1 for SitePad® System in eClinical Research

SitePad and patient-driven eData systems reduce trial costs and improves clinician and patient engagement on one of industry's thinnest, easy-to-use tablets

April 27, 2015 11:00 AM Eastern Daylight Time

BOSTON & GENEVA--()--PHT Corporation announced the selection of the Hewlett Packard (HP) ElitePad 1000 G2 with Windows 8.1 for its SitePad® System. The SitePad System replaces paper data collection methods in clinical trials that collect clinician- and patient-reported outcomes for supporting label claims of new drugs. PHT is the leading provider of mobile apps used to collect patient-driven eData for clinical research.

The SitePad System is used to collect clinician-driven endpoints such as disease progression, impression and assessments as well as patient reported outcomes and quality of life data directly from patients. The SitePad is configured to the requirements of clinical protocols and the study specific data collected is sent securely to StudyWorks™, the PHT online portal that provides real-time information about study compliance plus key measures used for operations and patient safety monitoring. Protocol compliance with the SitePad System exceeds 98.5% historically over 130 trials.

Demand for the PHT SitePad System has been growing steadily in recent years across therapeutic areas including oncology, immunology, and CNS. Clients are using the SitePad to increase the quality and efficiency of both patient and clinician reported outcomes across indications and do not want paper to be a rate limiting step in the clinical trial process. The SitePad System delivers higher quality data and faster time to data analysis for clinical trial sponsors. Watch a brief video: http://bit.ly/1cpCXcl

Sheila Rocchio, PHT Vice President of Marketing and Corporate Strategy, commented, "Sponsors and CROs rely on the SitePad System for trials of all types because it offers a reliable, easy-to-use and regulatory compliant method for increasing data quality and protocol compliance. The SitePad System supports risked based monitoring strategies by providing real-time access to endpoint data and has been proven to significantly reduce monitoring and data management costs. In a recent Phase III trial, using the SitePad was 30% more cost effective than using paper."

The HP ElitePad 1000 G2 contains an Intel® 64-bit Atom processor. It weighs 1.5 lbs. and is one of the thinnest tablets in the industry, at 9.2 mm. Features include wider viewing angles on the outdoor-viewable 10.1-inch diagonal WUXGA multi-touch panel; wireless connection, including optional worldwide 4G LTE with HP Connection Manager; and, support for touch, pen or voice-based input. The HP ElitePad 1000 G2 offers enhanced protection against virus attack, with a design that helps prevent data loss and reduce downtime.

Learn how Celgene Corporation used the SitePad System to save $13 million: http://www.phtcorp.com/PHT-Celgene-Case-Study-HPPR.aspx

About PHT Corporation

PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedInFacebookTwitterGoogle+ and YouTube.

Contacts

PHT Corporation
Brenda Nashawaty, 617-688-3253
[email protected]

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.